The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies

Natan Stein, Pinchas Tsukerman, Ofer Mandelboim*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


One of the most exciting fields in modern medicine is immunotherapy, treatment which looks to harness the power of the immune system to fight disease. A particularly effective strategy uses antibodies designed to influence the activity levels of the immune system. Here we look at two receptors-TIGIT and DNAM-1-which bind the same ligands but have opposite effects on immune cells, earning them the label 'paired receptors'. Importantly, natural killer cells and cytotoxic T cells express both of these receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. In this review we present cases in which the modulation of these receptors holds potential for the development of novel therapies.

Original languageAmerican English
Pages (from-to)111-119
Number of pages9
JournalHuman Antibodies
Issue number3-4
StatePublished - 24 Apr 2017

Bibliographical note

Publisher Copyright:
© 2016/2017 IOS Press and the authors. All rights reserved.


  • Autoimmune disease
  • Cancer
  • DNAM-1
  • Immunotherapy
  • NK cells


Dive into the research topics of 'The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies'. Together they form a unique fingerprint.

Cite this